Abstract 563P
Background
Around 1.9 million new cancer cases and around 930,000 deaths were attributed to colorectal cancer (CRC) worldwide in 2020. The European Union recommends population-based CRC screening. Reported long‘term results from various CRC screening programs are quite controversial as some of them report no survival gains. In June 2009 the CRC screening program was initiated in Lithuania. The aim of the study is to report the impact of CRC screening program on long-term mortality.
Methods
The anonymous data of the population aged 50-74 from the years 2013 to 2019, who participated in the CRC screening program were extracted from the statistical database of the National Health Insurance Fund, which provided both, the participation in different services of screening indicated by specific codes, and the mortality and survival marked in the database. For statistical analysis we divided patients in three groups: Negative fecal immunochemical test (FIT); positive FIT and screening colonoscopy performed; positive FIT and screening colonoscopy was not performed. The statistical analysis was performed using the R statistical software package v4.2.2.
Results
From the year 2013 to 2019 a total of 1,521551 people participated in the screening program. During the observation period 66920 (4.4%) patients died. The highest mortality was seen in patients that were diagnosed with cancer (19%). High mortality was seen in patients that did not proceed with further colonoscopy after a positive FIT. These patients had a significantly higher mortality rate: Negative FIT (4.2%) vs. Positive FIT + colonoscopy (4.9%) vs. Positive FIT - colonoscopy (8.6%); p<0.001. A univariate logistic regression analysis revealed that positive FIT + colonoscopy (OR 1.19 95% CI 1.15-1.24; p<0.001) and positive FIT - colonoscopy (OR 2.18 95% CI 2.12-2.24; p<0.001) groups had significantly increased mortality risks when compared to the negative FIT group.
Conclusions
Fully completed screening after a positive FIT result is associated with significantly reduced mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10